Gamida Cell (GMDA) Stock Forecast, Price Target & Predictions
GMDA Stock Forecast
Gamida Cell stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
GMDA Analyst Ratings
According to 2 Wall Street analysts, Gamida Cell's rating consensus is 'Buy'. The analyst rating breakdown for GMDA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 02, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 26, 2022 | JMP Securities | Buy | Buy | Hold |
Gamida Cell's last stock rating was published by Piper Sandler on Oct 02, 2022. The company gave GMDA a "Overweight" rating, the same as its previous rate.
Gamida Cell Financial Forecast
Gamida Cell Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $1.11M | - | - | - | - |
| Avg Forecast | $5.13M | $4.19M | $3.83M | $3.23M | $1.06M | $2.36M | $165.00K | $212.50K | $200.00K |
| High Forecast | $5.13M | $4.19M | $3.83M | $3.23M | $1.23M | $2.36M | $165.00K | $212.50K | $200.00K |
| Low Forecast | $5.13M | $4.19M | $3.83M | $3.23M | $887.92K | $2.36M | $165.00K | $212.50K | $200.00K |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | 1.04% | - | - | - | - |
Gamida Cell's average Quarter revenue forecast for Mar 24 based on 1 analysts is $3.23M, with a low forecast of $3.23M, and a high forecast of $3.23M. GMDA's average Quarter revenue forecast represents a 190.46% increase compared to the company's last Quarter revenue of $1.11M (Dec 23).
Gamida Cell EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | $-11.14M | - | - | - | $-8.31M |
| Avg Forecast | $3.08M | $2.51M | $2.30M | $1.94M | $638.25K | $1.42M | $99.00K | $127.50K | $-15.46M |
| High Forecast | $3.08M | $2.51M | $2.30M | $1.94M | $738.47K | $1.42M | $99.00K | $127.50K | $-12.37M |
| Low Forecast | $3.08M | $2.51M | $2.30M | $1.94M | $532.75K | $1.42M | $99.00K | $127.50K | $-18.55M |
| Surprise % | - | - | - | - | -17.46% | - | - | - | 0.54% |
undefined analysts predict GMDA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gamida Cell's previous annual EBITDA (undefined) of $NaN.
Gamida Cell Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | $-8.84M | - | - | - | $-10.60M |
| Avg Forecast | $-23.67M | $-22.91M | $-22.14M | $-20.62M | $-23.29M | $-25.58M | $-29.78M | $-47.09M | $-13.90M |
| High Forecast | $-23.67M | $-22.91M | $-22.14M | $-20.62M | $-23.29M | $-25.58M | $-29.78M | $-47.09M | $-11.12M |
| Low Forecast | $-23.67M | $-22.91M | $-22.14M | $-20.62M | $-23.29M | $-25.58M | $-29.78M | $-47.09M | $-16.68M |
| Surprise % | - | - | - | - | 0.38% | - | - | - | 0.76% |
Gamida Cell's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GMDA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Gamida Cell SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | $9.89M | - | - | - | $4.46M |
| Avg Forecast | $32.07M | $26.21M | $23.95M | $20.19M | $6.65M | $14.79M | $1.03M | $1.33M | $1.25M |
| High Forecast | $32.07M | $26.21M | $23.95M | $20.19M | $7.70M | $14.79M | $1.03M | $1.33M | $1.25M |
| Low Forecast | $32.07M | $26.21M | $23.95M | $20.19M | $5.55M | $14.79M | $1.03M | $1.33M | $1.25M |
| Surprise % | - | - | - | - | 1.49% | - | - | - | 3.57% |
Gamida Cell's average Quarter SG&A projection for Mar 24 is $20.19M, based on 1 Wall Street analysts, with a range of $20.19M to $20.19M. The forecast indicates a 104.06% rise compared to GMDA last annual SG&A of $9.89M (Dec 23).
Gamida Cell EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | $-0.04 | - | - | - | $-0.31 |
| Avg Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.15 | $-0.17 | $-0.20 | $-0.31 | $-0.46 |
| High Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.15 | $-0.17 | $-0.20 | $-0.31 | $-0.46 |
| Low Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.15 | $-0.17 | $-0.20 | $-0.31 | $-0.46 |
| Surprise % | - | - | - | - | 0.24% | - | - | - | 0.68% |
According to undefined Wall Street analysts, Gamida Cell's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GMDA previous annual EPS of $NaN (undefined).
Gamida Cell Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GMDA | Gamida Cell | $0.03 | $7.00 | 23233.33% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| LXRX | Lexicon Pharmaceuticals | $0.91 | $6.00 | 559.34% | Buy |
| INZY | Inozyme Pharma | $2.88 | $14.67 | 409.38% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.01 | $38.80 | 198.23% | Buy |
| TERN | Terns Pharmaceuticals | $5.70 | $14.25 | 150.00% | Buy |
| IOVA | Iovance Biotherapeutics | $8.43 | $21.00 | 149.11% | Buy |
| MCRB | Seres Therapeutics | $0.58 | $1.25 | 115.52% | Buy |
| ARDX | Ardelyx | $4.96 | $8.75 | 76.41% | Buy |
| IBRX | ImmunityBio | $5.01 | $8.00 | 59.68% | Buy |
| HOOK | HOOKIPA Pharma | $2.80 | $3.00 | 7.14% | Buy |